Clinical Study
Immune Response following Liver Transplantation Compared to Kidney Transplantation: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity and Cytochrome P450 3A5 Genotype Assay
Table 2
Backgrounds of KT patients.
| | Group KT-L () | Group KT-H () | value | | MK < 225 |
| | Average age | 48.8 (35–75) | 48.9 (22–68) | NS | | Male/female | 12/7 | 15/5 | NS | | Type of KT | | | | | Living donor KT | 2 (10.5%) | 7 (35%) | NS | | Deceased donor KT | 17 | 13 | | | ABO-incompatible | 4 (21.1%) | 3 (30%) | NS | | Tacrolimus use | 14 (73.7%) | 15 (75%) | NS | | CMV serology test | | | | | R-seropositive | 11 (68.7%) | 10 (66.7%) | NS | | D-positive/R-negative | 5 | 5 | | | R-CYP3A5 | | | | | *1*1 or *1*3 | 5 (45.5%) | 3 (33.3%) | NS | | *3*3 | 6 | 9 | | | Median months after KT | 19.1 (3.5–385) | 22.4 (1.2–322) | NS |
|
|
KT: kidney transplantation, IMK: ImmuKnow, CMV: cytomegalovirus, CYP3A5: cytochrome P450 3A5, R-: recipient, and D-: donor.
|
